Phase 1 study to evaluate [18F]ACI-19626 as a potential PET radioligand for imaging TDP-43 inclusions in the brain of patients with suspected TDP-43 proteinopathies compared with healthy controls

2024-513097-21-00 Protocol ACI-19626-FTD-2301 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 20 Nov 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol ACI-19626-FTD-2301

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 45
Countries 1
Sites 1

Alzheimer's Disease

Key facts

Sponsor
AC Immune SA
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
20 Nov 2024 → ongoing
Decision date (initial)
2024-10-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer's Disease

VersionLevelCodeTermSystem organ class
20.0 HLT 10012268 Dementia (excl Alzheimer's type) 10029205
20.0 LLT 10001896 Alzheimer's disease 10029205
21.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852
21.1 PT 10068968 Frontotemporal dementia 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AC Immune SA

Sponsor organisation
AC Immune SA
Address
Innovation Park
City
Lausanne
Postcode
1015
Country
Switzerland

Scientific contact point

Organisation
AC Immune SA
Contact name
Clinical Trial Information

Public contact point

Organisation
AC Immune SA
Contact name
Clinical Trial Information

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 45 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Amsterdam UMC
Radiology and Nuclear Medicine, De Boelelaan 1117, 1081 HV, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-11-20 2025-01-21

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-29 Netherlands Acceptable
2024-10-30
2024-10-30
2 SUBSTANTIAL MODIFICATION SM-1 2025-03-11 Netherlands Acceptable 2025-04-01